Gao M, Georgiou A, Lin VS, Jahja M, White CA, Anderson MA, McCormack MP, Roberts AW, Huang DCS, Thijssen R. Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications. British Journal of Haematology. 2024;:10.1111/bjh.19604
Yuan Z, van Delft MF, Li MX, Sumardy F, Smith BJ, Huang DCS, Lessene G, Khakam Y, Jin R, He S, Smith NA, Birkinshaw RW, Czabotar PE, Dewson G. Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis. PLOS Biology. 2024;22(5):10.1371/journal.pbio.3002617
Wang Z, Burigotto M, Ghetti S, Vaillant F, Tan T, Capaldo BD, Palmieri M, Hirokawa Y, Tai L, Simpson DS, Chang C, Huang AS, Lieschke E, Diepstraten ST, Kaloni D, Riffkin C, Huang DCS, Suen CSNLW, Garnham AL, Gibbs P, Visvader JE, Sieber OM, Herold MJ, Fava LL, Kelly GL, Strasser A. Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells. Cancer Discovery. 2024;14(2):10.1158/2159-8290.cd-23-0402
Galas-Filipowicz D, Chavda SJ, Gong J-N, Huang DCS, Khwaja A, Yong K. Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity. Frontiers in Oncology. 2024;14:10.3389/fonc.2024.1394393
Yang D, Li Q, Lu P, Wu D, Li W, Meng X, Xing M, Shangguan W, Chen B, Yang J, Zhang Z, Wang Z, Huang DCS, Zhao Q. FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma. Journal of Biological Chemistry. 2024;300(1):10.1016/j.jbc.2023.105535
Lew TE, Van Delft M, Riffkin C, Angela G, White C, Yuan Y, Michelle J, Anderson MA, Thijssen R, Huang DCS, Dawson MA, Roberts AW. Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers. Blood. 2023;142(Supplement 1):10.1182/blood-2023-184392
Xu J, Dong X, Huang DCS, Xu P, Zhao Q, Chen B. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers. 2023;15(20):10.3390/cancers15204957
Teh CE, Peng H, Luo M-X, Tan T, Trussart M, Howson LJ, Chua CC, Muttiah C, Brown F, Ritchie ME, Wei AH, Roberts AW, Bryant VL, Anderson MA, Lindeman GJ, Huang DCS, Thijssen R, Gray DHD. Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells. Blood Advances. 2023;7(12):10.1182/bloodadvances.2022008221
Pierotti CL, Jacobsen AV, Grohmann C, Dempsey RK, Etemadi N, Hildebrand JM, Fitzgibbon C, Young SN, Davies KA, Kersten WJA, Silke J, Lowes KN, Sabroux HJ, Huang DCS, van Delft MF, Murphy JM, Lessene G. The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase. Biochemical Journal. 2023;480(9):10.1042/bcj20230035
Zeng X, Yao B, Liu J, Gong G-W, Liu M, Li J, Pan H-F, Li Q, Yang D, Lu P, Wu D, Xu P, Chen B, Chen P, Zhang M, Zen K, Jing J, Huang DCS, Chen D, Jiang Z-W, Zhao Q. The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer. npj Precision Oncology. 2023;7(1):10.1038/s41698-023-00367-y
